Readers' Comments
Article: Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Back to article
|
View all comments
Author:
Elizabeth M. Swisher, MD | April 12, 2017
Submit your opinion:
You must be logged in to post a comment. Please
log in or
sign up for a free account.
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community
-
Editorial activities: Publish, peer review, edit
online articles.
-
Ask a Doctor Teams: Respond to patient questions and
discuss challenging presentations with other members.
Doctors Lounge Membership Application
